Overview
- 8 FDA inspections are on record.
- 6 inspections produced a Form 483.
- The most recent recorded inspection date is 2025-11-20.
At a glance
Inspections
8
Form 483s
6
EIRs
0
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 12 Nov 2025 – 20 Nov 2025 | Human Drugs | 483 | View 483 → |
| 17 Nov 2023 – 21 Nov 2023 | Human Drugs | 483 | View 483 → |
| 14 Feb 2022 – 18 Feb 2022 | Human Drugs | 483 | View 483 → |
| 26 Apr 2021 – 28 Apr 2021 | Human Drugs | Clean | |
| 2 Dec 2019 – 20 Dec 2019 | Human Drugs | 483 | View 483 → |
| 15 Apr 2019 – 19 Apr 2019 | Human Drugs | Clean | |
| 3 Dec 2018 – 13 Dec 2018 | Human Drugs | 483 | View 483 → |
| 26 Oct 2015 – 6 Nov 2015 | Human Drugs | 483 | View 483 → |
Observations on record
Form 483 observations cited at this site, most recent first.
20 Nov 2025
21 CFR 211.22(a)
Authority lacking to review records, investigate errors
Cited by Pushpa S Jayasekara
Investigators
FDA investigators tied to this site in the record.
Pushpa S Jayasekara2 insp.
Young M Yoon2 insp.
Yaharn Su1 insp.
Olumide A Akinyemi1 insp.
Johnny D Nwankwo1 insp.
Mindy M Chou1 insp.
Natasha Gupta1 insp.
David A Oluwo1 insp.
Anitha P Govada1 insp.
Melanie N Daniels1 insp.
David L Chon1 insp.
Marcus A Ray1 insp.
Tajah L Blackburn1 insp.
Rachel C Harrington1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.67(b) | Cited across public-safe Form 483 observations | 6x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 5x |
| 21 CFR 211.22(d) | Cited across public-safe Form 483 observations | 5x |
| 21 CFR 211.63 | Cited across public-safe Form 483 observations | 3x |
| 21 CFR 211.100(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.160(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.166(a)(2) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.188 | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.194(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.42(c)(2) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.68(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.68(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.160(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.194(a)(8) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.22(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.67(a) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind WES Pharma Inc.'s 6 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat